Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

Inclusion Criteria: * nAMD patients who, in the opinion of the Investigator, are inadequately responding to or failed current treatment options. * Active choroidal neovascularization (CNV) associated with age-related macular degeneration as evidenced on FA and SD-OCT at Day 1, including presence of intraretinal or subretinal fluid. * BCVA in the study eye (most affected) of 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or worse at screening and on Day 1. * Patients who have the capacity to give informed consent and who are willing and able to comply with all study-related procedures and assessments. Exclusion Criteria: * Any ocular/intraocular/periocular infection or inflammation in either eye in the past 4 weeks prior to screening. * Subretinal hemorrhage with bleeding area ≥4 disc area in the study eye * Concomitant therapy with anti-VEGF therapies (e.g., Avastin®, Lucentis®, or Eylea®) or previous use of these agents in the study eye within approximately 28 days of study enrollment * Any retinovascular disease or retinal degeneration other than nAMD in the study eye. * History of systemic and intraocular steroid use for 6 months prior to Day 1. The use of intravitreal nonbiodegradable steroid implants (ex. Iluvien®, Yutiq®, Retisert®) is prohibited. * Significant media opacities, including cataract, which might interfere with VA, assessment of toxicity, or fundus imaging. * Any uncontrolled medical condition that, in the opinion of the investigator, would preclude participation in this study.